Document is current
Any future updates will be listed below
-
Authors
Ng, Jane W. Y.
Felix, Janine F.
Olson, David M.
-
Funding
Funding for this research was provided by:
Molly Towell Perinatal Research Foundation
European Union Horizon 2020 Research & Innovation Programme (733206)
Department of Physiology, University of Alberta
Faculty of Medicine and Dentistry, University of Alberta
European Union, Marie Curie International Research Exchange Program
- License Information
-
More Information
Article History
Received: 2 February 2023
Accepted: 9 November 2023
First Online: 27 November 2023
Declarations
:
: Ethical approval for the ALSPAC study was obtained from the ALSPAC Law and Ethics committee and local research ethics committees (NHS Haydock REC: 10/H1010/70). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. At age 18, study children were sent “fair processing” materials describing ALSPAC’s intended use of their health and administrative records and were given clear means to consent or object via a written form. Data were not extracted for participants who objected or who were not sent fair processing consent for biological samples was collected in accordance with the Human Tissue Act (2004).The Generation R study protocol was approved by the Medical Ethical Committee of Erasmus MC, University Medical Centre Rotterdam. Written informed consent was obtained for all participants.
: Not applicable.
: DMO is the founder and CEO of Livmor Diagnostics, Inc., and the founder and Scientific Officer of Maternica Therapeutics, Inc. Neither organisation was involved or will benefit from this research. The other authors declare that they have no competing interests.
